Haemonetics Corporation Q4 FY2026 earnings call

Chris Simon mentioned Q4 revenue $346M, up 5% reported and 9% organic ex-CSL, adjusted EPS $1.29. Full year revenue $1.3B, adjusted EPS $4.96. Strength in core platforms like Plasma and TAG. Hospital business results discussed, including blood management and interventional technologies. Plasma momentum with growth driven by category leadership. James Dureka talked about adjusted gross margin, operating expenses, cash flow, and fiscal 2027 guidance.

Hospital revenue: Q4 $160M, full year $588M; 8% Q4 growth, 4% full year growth (7% and 4% organic). Blood management technologies: Q4 record quarter, 21% growth; hemostasis management high teens growth, transfusion management outsized growth. Interventional technologies: Q4 -10% revenue, full year -9% revenue; vascular closure down, EP affected by share loss and procedure dynamics. Plasma and blood center: Plasma Q4 $130M, up 3% reported, 13% organic ex-CSL; full year $524M, down 2% reported, up 20% organic ex-CSL. Blood Center Q4 $56M, up 1% reported, 6% organic; full year $221M, down 15% reported, up 5% organic.

Fiscal 2027 revenue growth 4 - 7% reported and 3 - 6% organic. Adjusted operating margin to improve 50 - 100 basis points. Adjusted EPS to grow broadly in line with revenue. Free cash flow conversion approximately 80%.

Q: On plasma U.S. collection volume trends and end market views for 2027, A: FY27 guide focuses on controllable factors, Persona Plus rollout, mid-single-digit growth with upside if collection trends strong.

Q: On margins and 2027 guide, A: Q4 operating margins lower due to tariffs, higher claims expense, sales and marketing investment; FY27 operating margin expansion driven by gross margin improvement and operating leverage.

Q: On hospital interventional tech trajectory, A: IVT turning corner, lapped headwinds, return to growth expected.

Q: On plasma landscape, A: Bullish on plasma, positive on IG-derived therapy demand.

Q: On MVP EP volumes, A: Market for EP volumes expected to grow mid-to-high single digits.

Q: On Percocil launch, A: Guidance reflects resourcing for launch, no revenue included yet.

Q: On plasma margin clarification and EPS growth, A: Plasma margin decline due to tariff, volume-based pricing; EPS growth commensurate with reported revenue growth.

Q: On plasma guide assumptions and residual impacts, A: FY27 clean print expected, fourth quarter seasonality, fog clearing on prior impacts.

Q: On Vivashore and Percocil early signals, A: Early signals positive, TAM estimated, working on integration.